Summary
Point-of-care testing (POCT), also known as bedside testing, near-patient testing, or decentralized laboratory testing, is an emerging specialty within in vitro diagnostics (IVD). POCT is one of the most rapidly growing areas in IVD, both due to the drive to increase efficiency and therefore improve patient care, and as a result of significant technological advances.
This report focuses on the POC diagnostics market in the 15 major markets (15MM: US, France, Germany, Italy, Spain, UK, Japan, China, India, Brazil, Canada, Mexico, Russia, South Korea, and Australia). In this report, GlobalData evaluates the currently marketed POC products, identifies the unmet needs in each market, analyzes market dynamics, and provides an understanding of physicians' adoption trends for different types of POC products. In order to successfully take advantage of the growing POC diagnostics market, manufacturers are required to adopt strategies that address the current unmet needs, and to concentrate on demonstrating the clinical value of their products, to drive physician adoption.
Highlights
Key Questions Answered
- What is the current and future cardiac marker POCT market outlook in the developed and emerging markets? What trends are affecting the global market?
- What is the competitive landscape and market share of major players in the cardiac marker POCT space across different regions?
- What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
- What are the unmet needs with the cardiac marker POC tests currently on the market?
- What are the key factors influencing a physician to use cardiac marker POC tests? What is physician perception and market outlook of these devices?
- What are the challenges and barriers that have hindered widespread adoption of cardiac marker POC devices?
Scope
- Competitive assessment: Currently marketed cardiac marker POC products and evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different cardiac marker POC devices
- Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Pipeline analysis: Emerging products and technologies.
- Annualized total cardiac marker POCT market revenue by segment and market outlooks by country from 2013-2022.
- Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the global market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Track device sales in the global market from 2014-2023
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
Companies Mentioned
Abbott Point of Care
Alere
LSI Medience
Philips Healthcare
Radiometer Medical
Response Biomedical
Roche Diagnostics
Siemens Healthineers
Trinity Biotech
'
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 15
2.1 POC Diagnostics Overview 15
2.2 Catalyst 16
2.3 Related Reports 17
3 Market Opportunities 18
3.1 Unmet Needs 18
3.1.1 Improved Reliability of Tests Outside Controlled Testing Environments 18
3.1.2 Data Management 18
3.1.3 Evidence of Cost-Effectiveness or Improved Patient Outcomes 19
3.1.4 Markers for Myocardial Ischemia 20
3.2 Market Drivers 21
3.2.1 Fast Turnaround Time 21
3.2.2 Use of POC Troponin Testing in Pre-hospital Settings 22
3.2.3 Increased Uptake of D-Dimer Testing 23
3.2.4 CLIA-Waived Status for POCT 23
3.2.5 Rising Prevalence of Diseases 24
3.3 Market Barriers 24
3.3.1 Management of POCT 24
3.3.2 Disruption to Traditional Ways of Working 25
3.3.3 Competition with Laboratory Tests 25
3.3.4 Regulatory Compliance 27
3.3.5 Cost and Reimbursement 27
3.3.6 Low Uptake of Novel Biomarkers 28
4 Market Access 29
4.1 Reimbursement Trends 29
4.1.1 North America 29
4.1.2 Europe 31
4.1.3 APAC 33
4.1.4 South America 35
4.2 Regulatory Issues and Recalls 36
4.3 Mergers, Acquisitions, and Key Partnerships 37
5 Competitive Assessment 39
5.1 Company Share Analysis 39
5.1.1 Global 39
5.1.2 US 40
5.1.3 Europe 40
5.1.4 Asia-Pacific and Rest of World 41
5.2 Major Players 42
5.2.1 Abbott Point of Care 42
5.2.2 Alere 45
5.2.3 LSI Medience 47
5.2.4 Philips Healthcare 50
5.2.5 Radiometer Medical 52
5.2.6 Response Biomedical 55
5.2.7 Roche Diagnostics 57
5.2.8 Siemens Healthineers 60
5.2.9 Trinity Biotech 62
6 Pipeline Assessment 65
6.1 Overview 65
6.2 Troponin Tests 66
6.3 BNP Tests 67
6.4 Panel Tests 68
6.5 Other Biomarkers 69
7 Procedure Trends 71
7.1 Troponin Tests 71
7.2 B-Type Natriuretic Peptide Tests 72
7.3 Other Cardiac Marker Tests 74
8 Market Outlook 76
8.1 Market Segment Analysis 76
8.2 Global Overview 77
8.3 US 79
8.4 Canada 81
8.5 Mexico 82
8.6 France 83
8.7 Germany 84
8.8 Italy 85
8.9 Russia 86
8.10 Spain 87
8.11 UK 89
8.12 Australia 90
8.13 China 91
8.14 Japan 93
8.15 India 94
8.16 South Korea 95
8.17 Brazil 96
9 Appendix 98
9.1 Bibliography 98
9.2 Abbreviations 102
9.3 Report Methodology 104
9.3.1 Overview 104
9.3.2 Coverage 104
9.3.3 Secondary Research 104
9.3.4 Forecasting Methodology 105
9.3.5 Primary Research - Key Opinion Leader Interviews 106
9.4 About the Authors 107
9.4.1 Analysts 107
9.4.2 Tyler Fletcher, Global Head of Medical Devices 108
9.5 About MediPoint 109
9.6 About GlobalData 109
9.7 Disclaimer 109
1.1 List of Tables
Table 1: Advantages and Disadvantages of POCT 16
Table 2: Regulatory Issues and Recalls 2012-2016 36
Table 3: Mergers, Acquisitions, and Key Partnerships, 2015-2016 38
Table 4: Company Profile - Abbott Point of Care 43
Table 5: Abbott Point of Care Portfolio Assessment, 2016 44
Table 6: SWOT Analysis - Abbott Point of Care 44
Table 7: Company Profile - Alere 45
Table 8: Alere POC Portfolio Assessment, 2016 46
Table 9: SWOT Analysis - Alere 47
Table 10: Company Profile - LSI Medience 48
Table 11: LSI Medience POC Portfolio Assessment, 2016 49
Table 12: SWOT Analysis - LSI Medience 50
Table 13: Company Profile - Philips Healthcare 51
Table 14: Philips Healthcare POC Portfolio Assessment, 2016 51
Table 15: SWOT Analysis - Philips Healthcare 52
Table 16: Company Profile - Radiometer Medical 53
Table 17: Radiometer Medical POC Portfolio Assessment, 2016 54
Table 18: SWOT Analysis - Radiometer Medical 54
Table 19: Company Profile - Response Biomedical 56
Table 20: Response Biomedical POC Portfolio Assessment, 2016 56
Table 21: SWOT Analysis - Response Biomedical 57
Table 22: Company Profile - Roche Diagnostics 58
Table 23: Roche Diagnostics POC Portfolio Assessment, 2016 59
Table 24: SWOT Analysis - Roche Diagnostics 59
Table 25: Company Profile - Siemens Healthineers 60
Table 26: Siemens Healthineers POC Portfolio Assessment, 2016 61
Table 27: SWOT Analysis - Siemens Healthineers 62
Table 28: Company Profile - Trinity Biotech 63
Table 29: Trinity Biotech POC Portfolio Assessment, 2016 64
Table 30: SWOT Analysis - Trinity Biotech 64
Table 31: Key Troponin POCT Pipelines, 2016 66
Table 32: Key BNP POCT Pipelines, 2016 67
Table 33: Key Cardiac Panel POCT Pipelines, 2016 68
Table 34: Key Other Cardiac Marker POCT Pipelines, 2016 69
Table 35: Troponin POCT Volume (thousands) Forecast by Country, 2014-2023 72
Table 36: BNP POCT Volume (thousands) Forecast by Country, 2014-2023 74
Table 37: Other Cardiac Marker POCT Volume (thousands) Forecast by Country, 2014-2023 75
Table 38: Global Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 76
Table 39: Global Cardiac Marker POCT Sales Forecast ($m) by Country, 2014-2023 78
Table 40: US Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 80
Table 41: Canada Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 81
Table 42: Mexico Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 82
Table 43: France Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 83
Table 44: Germany Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 84
Table 45: Italy Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 86
Table 46: Russia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 87
Table 47: Spain Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 88
Table 48: UK Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 89
Table 49: Australia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 91
Table 50: China Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 92
Table 51: Japan Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 93
Table 52: India Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 94
Table 53: South Korea Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 95
Table 54: Brazil Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 97
1.2 List of Figures
Figure 1: Global Company Share Analysis, 2016 39
Figure 2: US Company Share Analysis, 2016 40
Figure 3: Europe Company Share Analysis, 2016 41
Figure 4: APAC and Rest of World Company Share Analysis, 2016 42
Figure 5: Troponin POCT Volume (thousands) Forecast by Region, 2014-2023 71
Figure 6: BNP POCT Volume (thousands) Forecast by Region, 2014-2023 73
Figure 7: Other Cardiac Marker POCT Volume (thousands) Forecast by Region, 2014-2023 75
Figure 8: Cardiac Marker POCT Sales Forecast ($m), 2014-2023 77
Figure 9: Global Cardiac Marker POCT Market Share ($) by Country, 2016 79
Figure 10: US Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 80
Figure 11: Canada Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 81
Figure 12: Mexico Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 82
Figure 13: France Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 84
Figure 14: Germany Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 85
Figure 15: Italy Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 86
Figure 16: Russia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 87
Figure 17: Spain Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 88
Figure 18: UK Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 90
Figure 19: Australia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 91
Figure 20: China Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 92
Figure 21: Japan Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 93
Figure 22: India Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 95
Figure 23: South Korea Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 96
Figure 24: Brazil Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023 97
